Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients

Breast cancer (BC) categorized as human epidermal growth factor receptor 2 (HER2) borderline [2+ by immunohistochemistry (IHC 2+)] presents challenges for the testing, frequently obscured by intratumoral heterogeneity (ITH). This leads to difficulties in therapy decisions. We aimed to establish prog...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gedmante Radziuviene, Allan Rasmusson, Renaldas Augulis, Ruta Barbora Grineviciute, Dovile Zilenaite, Aida Laurinaviciene, Valerijus Ostapenko, Arvydas Laurinavicius
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
CD8
Acceso en línea:https://doaj.org/article/73d1a54944394a3f9f244347fdfc92a2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!